Major Depressive Disorder
Conditions
Interventions
Group 1: High-intensity interval training group (supervised, 3/week for 10 weeks)
Group 2: Stretching group (supervised, 3/week for 10 weeks)
Sponsors
Deutsche Sporthochschule Köln
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Participants must be native German speakers diagnosed with major depressive disorder by certified clinicians and be outpatients. To be recognised as suffering from Major Depressive Disorder (from mild to moderate), participants need to state at least five and a maximum of seven of nine symptoms of the DSM-5 depression definition nearly every day for at least two weeks. Medication: None or stable for at least two weeks before inclusion. If benzodiazepine or benzodiazepine-like medication: last intake maximum 24h before the beginning of the study. Assessment of the level of anti-depressive medication in the peripheral blood at inclusion and after completion of the study
Exclusion criteria
Exclusion criteria: - Physical exercise: Engaged in >2 h per week. - Body Mass Index: 30 kg/m2 - Comorbid diseases: Metabolic, hormonal, renal, intestinal, neuroendocrine diseases, chronic infection, drug addiction, or other diagnosed psychiatric disorders (e.g., bipolar disorder, personality disorder, psychosis) - Smoking: >20 cigarettes per day in the past three months - Alcohol use: AUDIT sum score >19 - Supplement: tryptophan-related supplements - Others: Pregnancy, Breastfeeding, Night-work shift
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study primarily aims to test if ten weeks of high-intensity interval training can concordantly regulate inflammatory-mediated changes in the kynurenine pathway and depressive symptoms in a sample of Major Depressive Disorder outpatients when compared to supervised active controls. These markers will be gathered at rest on fasted participants at baseline, after 5 weeks of training, and after 10 weeks of training (end of the intervention). The inflammation markers will be measured with Enzyme-Linked Immunosorbent Assay. The kynurenine markers will be assessed with High-Performance Liquid Chromatography-associated mass spectrometry. The depression symptoms will be assessed with self-reports and Clinician interviews. | — |
Secondary
| Measure | Time frame |
|---|---|
| An explorative analysis of methylation levels in promoters and polymorphic regions of the genes encoding for the major enzymes of the tryptophan pathways | — |
Countries
Germany
Contacts
Public ContactFlorian Javelle
Deutsche Sporthochschule Köln
Outcome results
None listed